Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer

Published:2020-03-26 Issue:9 Volume:7 Page:1903410
ISSN:2198-3844
Container-title:Advanced Science
language:en
Short-container-title:Adv. Sci.

Author:

Jia Qingzhu¹²,Chiu Luting³,Wu Shuangxiu³,Bai Jian³,Peng Lina¹²,Zheng Linpeng¹²,Zang Rui¹,Li Xueqin¹,Yuan Bibo¹,Gao Yixing¹²,Wu Dingyong¹,Li Xiaohong¹,Wu Lin³,Sun Jianguo¹²,He Ji⁴,Robinson Bruce W. S.⁵⁶,Zhu Bo¹²^ORCID

Affiliation:

1. Institute of Cancer Xinqiao Hospital The Army Medical University Xinqiao Main Street Chongqing 400037 China

2. Chongqing Key Laboratory of Immunotherapy Xinqiao Main Street Chongqing 400037 China

3. Berry Oncology Corporation NO. 4 Science Park Road, Changping District Beijing 102206 China

4. GeneCast Biotechnology Co., Ltd. 35 Huayuan North Road, HealthWork Suite 901 Beijing 100191 China

5. School of Medicine and Pharmacology University of Western Australia 35 Stirling Highway Perth Western Australia 6009 Australia

6. National Centre for Asbestos Related Diseases GPO Box U1908 Perth Western Australia 6845 Australia

Funder

Army Medical University

Foundation for Innovative Research Groups of the National Natural Science Foundation of China

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.201903410

Reference43 articles.

1. Immune checkpoint inhibitors: recent progress and potential biomarkers

2. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

3. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

4. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

5. The feasibility of using mutation detection in ctDNA to assess tumor dynamics

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer;Future Oncology;2024-07-29

2. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients;Clinical and Experimental Medicine;2024-03-30

3. Promising and Minimally Invasive Biomarkers: Targeting Melanoma;Cells;2023-12-20

4. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor;European Journal of Cancer;2023-12

5. PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer;Scientific Reports;2023-10-16